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multicistronic transgenes, and should be considered alongside other 
factors to guide the assembly of an optimal vectorized monoclonal 
antibody expression cassette.
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Promoters for Recombinant Adeno-Associated 
Viral (rAAV) Vectors
Sunghee Chai
Pediatrics, Oregon Health & Science University, Portland, OR
rAAVs have emerged as an efficient gene delivery tool. Discovery of 
various natural serotypes and recent development of recombinant 
capsids significantly advanced the transduction efficiency of rAAVs in 
a variety of cells and tissues. On the other hand, much less effort has 
been made for maximizing expression of the rAAV cargo DNA, since 
current AAV vectors mainly rely on well-established promoters for 
gene expression. Among those, CMV and CAG promoters belong to 
the most frequently used strong promoters providing universal activity. 
The capacity of DNA packaging in rAAV capsids is limited (4.7 kb). 
Hence, the large size of the existing strong promoters is a drawback 
in delivering genes and gene editing tools of large sizes, reaching the 
limits of the viral packaging capacity. To improve AAV as a gene therapy 
tool, discovery of small but strong promoters is a crucial step. Here 
we report two new strong mini promoters, called INS84 and GCG110, 
with universal activity in rAAV expression vectors. These promoters 
are only 84 and 135 base pairs in size, respectively. They showed strong 
expression of a reporter transgene from rAAV in human and mouse 
cells and tissues, including human hepatocytes in primary cultures, 
humanized mice in vivo and human pancreatic islet cells. Expression 
levels in these tissues were comparable to those obtained with the much 
larger CAG promoter. Until now, viral vectors utilized (or ‘borrowed’) 
promoters that are characterized in the context of plasmid expression 
vectors or germ-line transgenes. Our strong mini-promoters for 
rAAV expression suggest a new direction for developing promoters 
for viral vectors, specifically that the large size of promoters required 
for expression in the context of plasmid vectors is often not necessary 
for strong expression in an rAAV vector.
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Genetic access to specific cell types through minimally invasive routes 
is of particular interest in basic research and clinical applications. 
Extensive efforts have been made in engineering gene delivery 
vectors, such as recombinant adeno-associated viruses (rAAVs), 
and gene regulatory elements to achieve this goal. Despite many 
interesting candidates, revealed for example from directed evolution 
via M-CREATE (Sripriya Ravindra Kumar et al., Nature Methods, 
2020), histology-based characterization presents a bottleneck due to 
the limited number of variants and/or cell types that can be investigated 
at once. To address this, we have developed ultrasensitive sequential 
FISH (useqFISH) for multiplexed detection of both endogenous and 
barcoded transgene transcripts in intact tissue with single-molecule 
resolution. By combining two amplification strategies (rolling circle 
amplification, RCA, and hybridization chain reaction, HCR), we 
achieved a 2.7- or 6.7-fold increased signal-to-background ratio of 
useqFISH in comparison to one with RCA or HCR only amplification, 
respectively. UseqFISH allowed us to detect endogenous genes with 
a single probe pair (20-nucleotide (nt) for each) and, in transfected 
cell cultures, to distinguish capsid variants with genomes differing by 
only 7-mer peptide modification. We further improved useqFISH by 
establishing an automated single-molecule imaging and microfluidic 
solution exchange system and an analytical pipeline for 3D imaging 
data. To demonstrate the applicability of useqFISH for in vivo AAV 
profiling, we employed this method to further characterize a pool of 
6 AAV capsid variants that we found to be highly efficient for brain-
wide and/or cell-type biased transduction in the mouse brain following 
systemic delivery. We designed unique nucleic acid barcodes (160-nt) 
in the 3’UTR of each viral genome and retro-orbitally injected the 
pooled AAVs into 2 C57BL6/J mice at a dose of 5e10 viral genomes 
(vg) per variant (total 3e11 vg/mouse). For transcript detection, 11 
canonical cell-type markers (e.g., Slc17a7, Gad1, Pvalb, SST, VIP, etc) 
were used together with probes against the viral genome barcodes, to 
characterize the cell-type tropisms of each variant. Next, we designed 
a pool of 103 barcoded AAV genomes carrying 4 tandem repeats of a 
unique miRNA target site. We packaged these genomes into AAV-PHP.
eB and delivered to 3 C57BL6/J mice at a dose of 1e10 vg/variant (total 
~1e12 vg/mouse). Using useqFISH, we were able to assess the ability of 
each miRNA target site to dampen transgene expression in different cell 
types, thereby revealing useful intersectional strategies to refine cell-
type-specific transgene expression with capsid/cargo combinations. 
These results demonstrate that useqFISH allows for high-throughput 
characterization of pooled genetic variants of viral capsids and gene 
regulatory elements in intact tissue and thus enables comprehensive 
profiling of genetic toolkits for precise access to targets of interest.
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Recent years have seen significant progress in AAV capsid engineering 
for gene delivery with increased efficiency and desired cell-type 
specificity to match the needs of pre-clinical research and gene therapy. 
The cellular uptake of AAVs, however, can stop short of the ultimate 
goal of cargo protein production - due to AAV silencing, insufficient 
nuclear transport, inefficient uncoating, failed second-strand synthesis, 
or other still to be discovered mechanisms. Defining the relationship 
between AAV genome uptake, transcription and cargo protein synthesis 
efficiencies in different cell types and tissues can help bypass key 
bottlenecks in gene delivery and guide effective AAV engineering. 
We adapted a recently published in-situ-transcription-based signal 
amplification method, the “Zombie technique” (1), to detect AAV 
genomes in a variety of fixed cells and tissues. Zombie involves 
producing 20 to 380 base-pair long barcode transcripts by exogenously-
supplied T7 phage polymerase, which are then visualized at high 
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resolution in intact cells through fluorescent in situ hybridization 
(FISH) by hybridization chain reaction (HCR). We demonstrate that 
Zombie enables simultaneous detection of AAV genomes and AAV 
transcripts by FISH and cargo proteins by immunofluorescence. 
Consequently, we can determine the rates of AAV genome nuclear 
uptake, cargo transcription and cargo translation at different time points 
post-infection. Combining the Zombie method with cell-type-specific 
markers (protein immunolabelling or mRNA FISH) can give insights 
into subcellular AAV processing in complex tissues and help pinpoint to 
limiting factors in the overall transduction process. Interestingly, we find 
that after direct brain injection of AAV6, although cargo genomes do 
enter the nuclei of microglia, these genomes do not result in functional 
cargo protein production in this cell type. Furthermore, we analyze the 
pattern of AAV genome nuclear uptake, transcription and translation 
in mice after systemic delivery of AAV9 and engineered AAV capsids 
(AAV.PHP.eB, AAV.CAP-B10) (2, 3) across brain, liver and spleen. 
In conclusion, the Zombie technique adapted to AAV vectors enables 
simultaneous cargo genome, mRNA and protein visualization and 
thus can help differentiate cellular and subcellular processing steps of 
engineered gene delivery vectors, facilitating their refinement for basic 
and translational research.
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The use of adeno-associated virus (AAV) for gene therapy has been 
accelerated in recent years. Large-scale AAV vector production 
with consistent purity and potency remains a challenging hurdle 
to overcome. DNA deletions and mutations within the inverted 
terminal repeats (ITR) of the transgene plasmid can occur during 
bacterial plasmid amplification and AAV production processes thereby 
hampering vector quality. Here we describe engineered ITR transgene 
plasmids containing both stable and unstable ITR sequences and 
further evaluated AAV packaging quality and potency. The occurrence 
of ITR mutations and deletions within the stable ITR plasmid was 
confirmed to be significantly reduced during large-scale plasmid 
production and purification. Packaged ssDNA content in AAV vectors 
that were generated using various ITR plasmids was also examined 
by next-generation sequencing to identify transgene sequences and 
non-transgene DNA fragments. Moreover, we evaluated AAV vector 
potency in vitro and in vivo by measuring the expression and activity 
of a reporter gene under the control of various regulatory elements. 
Our results indicate that AAV vector production and potency benefits 
from the use of a stable ITR transgene plasmids.
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Recombinant AAV vectors are emerging as powerful delivery vehicles 
for human gene therapy, with three approved AAV gene therapy 
products to date and many more in clinical trials. In order to maximize 
the utility of AAV vector- mediated gene delivery, it is necessary to 
design the next generation AAV vectors with improved characteristics. 
Considerable attention has been focused on capsid engineering, 
however, of equal importance is the optimization of regulatory 
components of the AAV vector genome itself. In particular, novel 
constitutive synthetic promoters are needed that can be easily packaged 
into AAV vectors to improve transgene expression characteristics 
including cell-type specificity, prevent toxicity from overexpression 
and reduce innate immune responses to the promoter itself. Here, we 
describe a rational promoter engineering approach to generate short 
(300-700 bp) synthetic promoters for constitutive transgene expression 
from AAV vectors with enhanced expression profiles. Core promoters 
were subject to modification of key regulatory sites including the 
initiator site, TATA box, GC box and DPE site. In addition, 
various modified introns were inserted into the 5’ UTR region of 
these core promoters, and enhancer elements were added 
upstream of the modified core promoters. All candidates tested 
were first evaluated in vitro in HEK293T cells, using a dual 
luciferase expression system and compared to the commonly used 
strong tCAG promoter and the weak EFS promoter. Novel 
synthetic promoters that were between 300-700 bp in size, 
demonstrated increased expression compared to EFS, and showed 
a larger dynamic range of expression with less saturation 
compared to EFS and tCAG were then selected for testing in vivo. 
AAV vectors with candidate engineered synthetic promoters 
driving fluorescent reporter transgenes were packaged into 
different serotypes and delivered to the CNS and muscle of mice. 
From this study we identified novel short synthetic promoters 
that demonstrated improved transgene expression characteristics 
compared to existing constitutive promoters both in vitro and in 
vivo.
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